LT3513806T - Imunogeninė kompozicija - Google Patents

Imunogeninė kompozicija

Info

Publication number: LT3513806T
Authority: LT; Lithuania
Prior art keywords: immunogenic composition; immunogenic; composition
Prior art date: 2012-12-05

Application number

LTEP19159001.7T

Other languages

English (en)

Inventor

Dominique Boutriau

Sophie Marie Jeanne Valentine Germain

Hugues WALLEMACQ

Original Assignee

Glaxosmithkline Biologicals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-05

Filing date

2013-12-03

Publication date

2023-04-11

2013-12-03 Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa

2023-04-11 Publication of LT3513806T publication Critical patent/LT3513806T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

LTEP19159001.7T 2012-12-05 2013-12-03 Imunogeninė kompozicija LT3513806T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB201221875		2012-12-05

Publications (1)

Publication Number	Publication Date
LT3513806T true LT3513806T (lt)	2023-04-11

Family

ID=49724573

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP13801540.9T LT2928489T (lt)	2012-12-05	2013-12-03	Imunogeninė kompozicija
LTEP19159001.7T LT3513806T (lt)	2012-12-05	2013-12-03	Imunogeninė kompozicija

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP13801540.9T LT2928489T (lt)	2012-12-05	2013-12-03	Imunogeninė kompozicija

Country Status (22)

Country	Link
US (2)	US9694064B2 (lt)
EP (2)	EP3513806B1 (lt)
JP (2)	JP6290918B2 (lt)
CN (2)	CN104884081A (lt)
AR (1)	AR093712A1 (lt)
AU (1)	AU2013354186A1 (lt)
BR (1)	BR112015012841B1 (lt)
CA (1)	CA2893435A1 (lt)
CY (1)	CY1121560T1 (lt)
DK (2)	DK3513806T5 (lt)
ES (2)	ES2939307T3 (lt)
FI (1)	FI3513806T3 (lt)
HR (2)	HRP20230359T1 (lt)
HU (2)	HUE043091T2 (lt)
LT (2)	LT2928489T (lt)
PL (2)	PL3513806T3 (lt)
PT (2)	PT3513806T (lt)
SG (1)	SG11201503861UA (lt)
SI (2)	SI3513806T1 (lt)
TR (1)	TR201905272T4 (lt)
WO (1)	WO2014086787A1 (lt)
ZA (1)	ZA201503927B (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2878307B1 (en) *	2005-06-27	2019-07-24	GlaxoSmithKline Biologicals S.A.	Immunogenic composition
US9598472B2 (en)	2010-09-03	2017-03-21	Valneva Austria Gmbh	Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
TWI804717B (zh)	2011-04-22	2023-06-11	美商惠氏有限責任公司	與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
BR122016023101B1 (pt) *	2012-10-21	2022-03-22	Pfizer Inc	Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
LT2928489T (lt) *	2012-12-05	2019-04-10	Glaxosmithkline Biologicals S.A.	Imunogeninė kompozicija
CA2952118A1 (en) *	2014-06-25	2015-12-30	Glaxosmithkline Biologicals S.A.	Clostridium difficile immunogenic composition
WO2016012587A1 (en) *	2014-07-25	2016-01-28	Biosynth S.R.L.	Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
US10533036B2 (en)	2015-02-19	2020-01-14	Immune Biosolutions Inc	Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
CA3014498A1 (en)	2016-03-21	2017-09-28	Children's Medical Center Corporation	Compositions and methods for inhibiting wnt signaling
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
BR112019019117A2 (pt) *	2017-03-15	2020-05-05	Novavax Inc	métodos e composições para induzir respostas imunes contra clostridium difficile
CN107397956A (zh) *	2017-08-08	2017-11-28	南开大学	一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
CN112512556A (zh)	2018-01-16	2021-03-16	儿童医学中心公司	用于抑制wnt信号传导的组合物和方法
GB201804092D0 (en) *	2018-03-14	2018-04-25	Imperial Innovations Ltd	Methods and compositions
US10933126B2 (en)	2018-05-03	2021-03-02	The Board Of Regents Of The University Of Oklahoma	Clostridium difficile immunogenic compositions and methods of use
JP7637988B2 (ja) *	2019-05-21	2025-03-03	ザリージェンツオブザユニバーシティオブカリフォルニア	クロストリジウム・ディフィシルのワクチン組成物
US20230218735A1 (en) *	2020-06-19	2023-07-13	Pfizer Inc.	Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
US20240189410A1 (en) *	2022-12-13	2024-06-13	Pfizer Inc.	Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2024160901A1 (en)	2023-02-02	2024-08-08	Glaxosmithkline Biologicals Sa	Immunogenic composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
WO1988009797A1 (en)	1987-06-05	1988-12-15	The United States Of America, As Represented By Th	Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
EP0382271B1 (en)	1989-02-04	1994-12-21	Akzo Nobel N.V.	Tocols as adjuvant in vaccine
CA2017507C (en)	1989-05-25	1996-11-12	Gary Van Nest	Adjuvant formulation comprising a submicron oil droplet emulsion
JP3755890B2 (ja)	1992-06-25	2006-03-15	スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム）	アジュバント含有ワクチン組成物
WO1994021292A1 (en)	1993-03-23	1994-09-29	Smithkline Beecham Biologicals (S.A.)	Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
AU709586B2 (en)	1994-10-24	1999-09-02	Ophidian Pharmaceuticals, Inc.	Vaccine and antitoxin for treatment and prevention of C. difficile disease
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP2305293A3 (en)	1997-10-20	2013-11-06	Sanofi Pasteur Biologics Co.	Immunization against Clostridium difficile disease
EP1169456B1 (en)	1999-04-09	2012-07-11	Intercell USA, Inc.	Recombinant production of Clostridium difficile Toxin A or Toxin B
US6733760B1 (en) *	1999-04-09	2004-05-11	Techlab, Inc.	Recombinant toxin A/toxin B vaccine against Clostridium difficile
WO2001073030A2 (en)	2000-03-28	2001-10-04	Diadexus, Inc.	Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) *	2005-03-23	2009-01-29	Glaxosmithkline Biologicals, S.A.	Novel use
GB0525321D0 (en) *	2005-12-13	2006-01-18	Glaxosmithkline Biolog Sa	Novel compositions
TWI457133B (zh) *	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
JP5230632B2 (ja) *	2006-10-12	2013-07-10	グラクソスミスクラインバイオロジカルズソシエテアノニム	水中油型エマルジョンアジュバントを含むワクチン
GB0711858D0 (en)	2007-06-19	2007-07-25	Glaxosmithkline Biolog Sa	Vaccine
ES2657485T3 (es)	2007-09-14	2018-03-05	Sanofi Pasteur Biologics, Llc	Composiciones farmacéuticas que contienen toxoides A y B de Clostridium difficile
DK2271360T3 (en) *	2008-04-16	2015-12-14	Glaxosmithkline Biolog Sa	Vaccine
EP2318515A4 (en) *	2008-08-06	2012-11-14	Emergent Product Dev Uk Ltd	DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE
US9598472B2 (en)	2010-09-03	2017-03-21	Valneva Austria Gmbh	Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
HRP20231749T1 (hr) *	2011-05-27	2024-03-15	Glaxosmithkline Biologicals Sa	Imunogeni pripravak
LT2928489T (lt) *	2012-12-05	2019-04-10	Glaxosmithkline Biologicals S.A.	Imunogeninė kompozicija

2013
- 2013-12-03 LT LTEP13801540.9T patent/LT2928489T/lt unknown
- 2013-12-03 ES ES19159001T patent/ES2939307T3/es active Active
- 2013-12-03 PT PT191590017T patent/PT3513806T/pt unknown
- 2013-12-03 PL PL19159001.7T patent/PL3513806T3/pl unknown
- 2013-12-03 DK DK19159001.7T patent/DK3513806T5/da active
- 2013-12-03 WO PCT/EP2013/075405 patent/WO2014086787A1/en active Application Filing
- 2013-12-03 PT PT13801540T patent/PT2928489T/pt unknown
- 2013-12-03 PL PL13801540T patent/PL2928489T3/pl unknown
- 2013-12-03 CA CA2893435A patent/CA2893435A1/en active Pending
- 2013-12-03 CN CN201380063596.3A patent/CN104884081A/zh active Pending
- 2013-12-03 CN CN202011473000.5A patent/CN112807422A/zh active Pending
- 2013-12-03 HU HUE13801540A patent/HUE043091T2/hu unknown
- 2013-12-03 HU HUE19159001A patent/HUE061273T2/hu unknown
- 2013-12-03 FI FIEP19159001.7T patent/FI3513806T3/fi active
- 2013-12-03 SI SI201332035T patent/SI3513806T1/sl unknown
- 2013-12-03 JP JP2015545783A patent/JP6290918B2/ja active Active
- 2013-12-03 SG SG11201503861UA patent/SG11201503861UA/en unknown
- 2013-12-03 DK DK13801540.9T patent/DK2928489T3/en active
- 2013-12-03 BR BR112015012841-6A patent/BR112015012841B1/pt active IP Right Grant
- 2013-12-03 EP EP19159001.7A patent/EP3513806B1/en active Active
- 2013-12-03 AU AU2013354186A patent/AU2013354186A1/en not_active Abandoned
- 2013-12-03 HR HRP20230359TT patent/HRP20230359T1/hr unknown
- 2013-12-03 EP EP13801540.9A patent/EP2928489B1/en active Active
- 2013-12-03 ES ES13801540T patent/ES2721930T3/es active Active
- 2013-12-03 SI SI201331393T patent/SI2928489T1/sl unknown
- 2013-12-03 LT LTEP19159001.7T patent/LT3513806T/lt unknown
- 2013-12-03 AR ARP130104466A patent/AR093712A1/es unknown
- 2013-12-03 TR TR2019/05272T patent/TR201905272T4/tr unknown
- 2013-12-03 US US14/649,940 patent/US9694064B2/en active Active
2015
- 2015-06-01 ZA ZA2015/03927A patent/ZA201503927B/en unknown
2017
- 2017-05-26 US US15/606,439 patent/US10130694B2/en active Active
2018
- 2018-02-08 JP JP2018020900A patent/JP6626521B2/ja active Active
2019
- 2019-04-16 HR HRP20190711TT patent/HRP20190711T1/hr unknown
- 2019-04-19 CY CY20191100436T patent/CY1121560T1/el unknown

Also Published As

Publication number	Publication date
CN112807422A (zh)	2021-05-18
EP3513806B1 (en)	2023-01-25
DK3513806T3 (da)	2023-02-27
SI2928489T1 (sl)	2019-05-31
US20170340719A1 (en)	2017-11-30
WO2014086787A1 (en)	2014-06-12
DK3513806T5 (da)	2024-09-02
HRP20230359T1 (hr)	2023-06-09
ZA201503927B (en)	2017-11-29
HUE043091T2 (hu)	2019-08-28
JP6626521B2 (ja)	2019-12-25
EP2928489A1 (en)	2015-10-14
ES2721930T3 (es)	2019-08-06
EP2928489B1 (en)	2019-02-27
CN104884081A (zh)	2015-09-02
HRP20190711T1 (hr)	2019-05-31
PT3513806T (pt)	2023-03-02
US20150313984A1 (en)	2015-11-05
PT2928489T (pt)	2019-05-28
HUE061273T2 (hu)	2023-06-28
CA2893435A1 (en)	2014-06-12
JP2016502551A (ja)	2016-01-28
AU2013354186A1 (en)	2014-06-12
BR112015012841B1 (pt)	2022-05-03
US9694064B2 (en)	2017-07-04
FI3513806T3 (fi)	2023-04-26
SI3513806T1 (sl)	2023-04-28
ES2939307T3 (es)	2023-04-20
EP3513806A1 (en)	2019-07-24
US10130694B2 (en)	2018-11-20
PL2928489T3 (pl)	2019-07-31
JP2018104446A (ja)	2018-07-05
TR201905272T4 (tr)	2019-05-21
SG11201503861UA (en)	2015-06-29
JP6290918B2 (ja)	2018-03-07
BR112015012841A2 (pt)	2017-09-26
AR093712A1 (es)	2015-06-17
LT2928489T (lt)	2019-04-10
CY1121560T1 (el)	2020-05-29
DK2928489T3 (en)	2019-04-23
PL3513806T3 (pl)	2023-05-15

Publication	Publication Date	Title
ZA201503927B (en)	2017-11-29	Immunogenic composition
SG11201404447WA (en)	2014-08-28	Immunogenic composition
PL2647387T3 (pl)	2016-09-30	Kompozycja szczepionki
SG10201912291YA (en)	2020-02-27	Vaccine compositions
IL238079A0 (en)	2015-05-31	Immunogenic preparation
SG11201500979RA (en)	2015-07-30	Immunogenic composition
SMT201700110T1 (it)	2017-03-08	Composizione immunogena
GB201223342D0 (en)	2013-02-06	Immunogenic composition
GB201218660D0 (en)	2012-11-28	Immunogenic composition
GB201204968D0 (en)	2012-05-02	Immunogenic composition
GB201204851D0 (en)	2012-05-02	Immunogenic composition